Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene.
Cortisol resistance (CR) is a rare disease characterized by a generalized reduced sensitivity of end-organs to the actions of glucocorticoids (GCs). GC effects are mediated by the GC receptor (GR). The molecular alterations in CR described thus far were located in the hormone-binding domain of the GR gene. Recent reports of a considerable prevalence of abnormalities in the GR in patients attending the endocrine clinic prompted us to carry out further investigations with respect to GR protein and GR gene in patients attending the endocrine clinic for a broad spectrum of complaints and biochemical evidence suggesting a CR. In the present study, we describe five patients with biochemical and clinical CR. All patients showed a diurnal rhythm of serum cortisol concentrations (albeit at a high level), an insufficient suppression of serum cortisol concentration in reaction to 1 mg dexamethasone (DEX), and variable degrees of androgen overproduction, in the absence of clinical signs and symptoms of Cushing's syndrome. Three of the four female patients presented with complaints of androgen overproduction, two of them in combination with fatigue. The other female patient had severe steroid-resistant asthma. The only male patient and his son were asymptomatic. In four patients, we investigated receptor protein characteristics on mononuclear leukocytes in a whole cell DEX binding assay and studied the ability of DEX to inhibit mitogen-induced cell proliferation in mononuclear leukocytes in vitro. In all patients investigated, we found alterations in receptor number or ligand affinity and/or the ability of DEX to inhibit mitogen-induced cell proliferation. To investigate the molecular defects leading to the clinical and biochemical pictures in these patients, we screened the GR gene using PCR/single-strand conformational polymorphism/sequence analysis. No GR gene alterations were found in these patients. In conclusion, the five patients described had clinical and biochemical evidence of CR, but no abnormalities were demonstrated in the GR gene. Probably, as yet undefined alterations somewhere in the cascade of events starting with ligand binding to the GR protein, and finally resulting in the regulation of the expression of GC responsive genes, or postreceptor defects or interactions with other nuclear factors form the pathophysiologic basis of CR in these patients.
Huizenga
N A
NA
Department of Internal Medicine III, University Hospital Dijkzigt, Rotterdam, The Netherlands.
de Lange
P
P
Koper
J W
JW
de Herder
W W
WW
Abs
R
R
Kasteren
J H
JH
de Jong
F H
FH
Lamberts
S W
SW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000728:Androgens / Q000096:biosynthesis; D003907:Dexamethasone / Q000493:pharmacokinetics / Q000494:pharmacology; D004351:Drug Resistance; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology / Q000502:physiology*; D006628:Hirsutism; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology / Q000502:physiology*; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology; D008297:Male; D008599:Menstruation Disturbances; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011965:Receptors, Glucocorticoid / Q000235:genetics*
D000728:Androgens; D005938:Glucocorticoids; D011965:Receptors, Glucocorticoid; D003907:Dexamethasone; D006854:Hydrocortisone